Alexion Pharma (ALXN) Tops Q4 EPS by 20c, FY Guidnace Misses

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $1.48, $0.20 better than the analyst estimate of $1.28. Revenue for the quarter came in at $909.7 million versus the consensus estimate of $880.65 million.

GUIDANCE:

Alexion Pharma sees 2018 EPS of $6.60-$6.80, versus the consensus of $7.01. Alexion Pharma sees 2018 revenue of $3.85-3.95 billion, versus the consensus of $4.07 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79